RAPS's weekly FDA roundup covers the citizen petition, new warning letters for manufacturing and lab violations, and a bipartisan clinical trial bill.
Recap by typeshit. Full story at RAPS.
Strive Specialties failed to revive its suit over GLP-1 competition. Novo still faces soft 2026 forecasts and an exploratory CagriSema analysis in women.
Reports say RFK Jr. backs an interim path for specialty compounding, while the FDA lists BPC-157 as a possible safety risk and doctors cite thin human evidence.
Belga reports the number of seized weight loss drugs in Belgium went up again, with officials concerned about an unofficial parallel market.
Clinics took about 60% of supply, and one Seoul clinic got more Mounjaro than 174 hospitals combined. The health ministry warns of sanctions and criminal referrals.
She suggests following muscle mass, body fat and body water too, for a clearer view of how the body changes over time on treatment.
McGill researchers pooled data on 25,816 adults. Amycretin reached about 23.9% placebo-subtracted loss and retatrutide about 22.1%, though trials differed.
Loading…